These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11876698)

  • 1. Integrated acidity and rabeprazole pharmacology.
    Gardner JD; Perdomo C; Sloan S; Hahne WF; Barth JA; Rodriguez-Stanley S; Robinson M
    Aliment Pharmacol Ther; 2002 Mar; 16(3):455-64. PubMed ID: 11876698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
    Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ
    Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
    Gardner JD; Sloan S; Miner PB; Robinson M
    Aliment Pharmacol Ther; 2003 Apr; 17(7):955-64. PubMed ID: 12656698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease.
    Gardner JD; Sloan S; Miner PB; Robinson M
    Aliment Pharmacol Ther; 2003 Apr; 17(7):945-53. PubMed ID: 12656697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
    Gardner JD; Gallo-Torres H; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2003 Nov; 18(9):891-905. PubMed ID: 14616153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
    Galmiche JP; Zerbib F; Ducrottè P; Fournet J; Rampal P; Avasthy N; Humphries TJ
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1343-50. PubMed ID: 11552904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
    Gardner JD; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1381-6. PubMed ID: 15606401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects.
    Williams MP; Blanshard C; Millson C; Sercombe J; Pounder RE
    Aliment Pharmacol Ther; 2000 Jun; 14(6):691-9. PubMed ID: 10848651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
    Katz PO; Hatlebakk JG; Castell DO
    Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
    Williams MP; Sercombe J; Hamilton MI; Pounder RE
    Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
    Pehlivanov ND; Olyaee M; Sarosiek I; McCallum RW
    Aliment Pharmacol Ther; 2003 Nov; 18(9):883-90. PubMed ID: 14616152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
    Gardner JD; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2003 Jul; 18(1):133-40. PubMed ID: 12848635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study.
    Vo L; Simonian HP; Doma S; Fisher RS; Parkman HP
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1321-30. PubMed ID: 15932362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
    Miner P; Delemos B; Xiang J; Lococo J; Ieni J
    Aliment Pharmacol Ther; 2010 May; 31(9):991-1000. PubMed ID: 20132153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
    Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
    Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.
    Ohning GV; Barbuti RC; Kovacs TO; Sytnik B; Humphries TJ; Walsh JH
    Aliment Pharmacol Ther; 2000 Jun; 14(6):701-8. PubMed ID: 10848652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.